Confidence Pharmaceutical Research

Rescue success story – how we helped turn this study around  120 patients in 2 years → 400 in 1 year This global Phase III infectious disease study had lost momentum, enrolling only 120 patients in two years and falling far short of sponsor goals. Confidence stepped in to re-assess feasibility, re-energize sites, and rebuild investigator trust. Within a year, enrollment didn’t just recover — it quadrupled, reaching 400 patients. This effort was more than a rescue. It was a rejuvenation — rewriting the story from slow decline to strong finish. #StudyRescue #InfectiousDisease #ClinicalTrials #ClinicalHighlights #CRO

Too often, global enrollment challenges trigger drastic regional moves—closing a country, shifting timelines, or rebalancing global targets. But there’s another way. In the second chapter of our Rescue Studies blog series, CRO Changeovers That Work, we explore how a targeted, country-level pivot can revive enrollment without sacrificing your global footprint. From second-opinion feasibility to seamless CRO transitions and site revitalization, we show how rethinking a single region can realign an entire study. This series is about more than “fixing problems”—it’s about turning slowdowns into momentum, one region at a time. Read the full article here: https://lnkd.in/eXzPfN4K #ClinicalResearch #RescueStudies #ClinicalTrials #CRO #PatientEnrollmen

We recently wrapped up a study where we went from start-up to first patient in just 48 days 🚀 That timeline is something we’re truly proud of. But what matters just as much is what came out of it: genuine partnerships. One of our collaborators said it best: “Confidence is much more than a CRO: they are a partner that delivers and builds relationships!!” Moments like this remind us why we do what we do. It’s not only about the numbers – it’s about trust, teamwork, and making research happen together. #ClinicalResearch #SiteActivation #CROPartner #ClinicalTrials #Collaboration

Phase 1 vaccine trial for infectious disease: 60 patients enrolled in one month! From activation to full enrollment in just one month, Confidence delivered record speed without compromising quality. Site activation in the U.S. was achieved in only 3 weeks — including full EDC build — thanks to streamlined startup processes and strong site communication. The sponsor highlighted this study as proof that early-phase trials don’t need to drag. This is how planning should be — clear, realistic, and built to deliver results. #ClinicalTrials #VaccineStudies #CRO #ClinicalHighlights #VaccineTrials

Across the world, new life science ecosystems are being built with government support, academic partnerships, and startup momentum. But for these regions to truly thrive, service providers — CROs, consultants, clinical sites — must show up early and help turn promise into performance. At Confidence Pharmaceutical Research, we see these hubs as more than markets — they’re ecosystems in the making. Our latest blog dives into: - What makes a biotech hub - Why service providers have a pivotal role - Opportunities at home and abroad - How CROs like Confidence assess operational readiness in emerging regions If you're working in an emerging biotech hub—or helping one grow—this piece is for you. 🔗 Read the full blog: [https://lnkd.in/edwZgGmj] #ClinicalResearch #Biotech #CRO #DrugDevelopment #EmergingMarkets #Feasibility #LifeSciences #ConfidenceCRO #BiotechHubs

Rare and ultra-rare studies come with extraordinary urgency and complexity. Yet the biggest challenge isn’t always scientific—it’s finding, enrolling, and retaining the right patients. We’re launching a new blog series: Patient Enrollment & Retention in Rare Disease Studies. In Part 1, we explore why rare disease enrollment is so challenging, the diverse realities of rare patient populations, and the specialized toolkit needed to reach, engage, and support them. From feasibility modeling and caregiver-inclusive designs to truly patient-centered materials, this series focuses on what it takes to build studies around the people, not just the protocol. Read the first installment here: https://lnkd.in/efREBc7P Stay tuned for Part 2, where we dive into the critical role of patient support organizations in rare disease trials. #rarestudies #patientenrollment #cro

Biotech funding is tighter than ever. But some companies are still moving forward. What are they doing differently? In our latest blog, we break down how early-stage biotech teams are navigating the current capital crunch — and what strategies separate those advancing from those hitting pause. - Strategic prioritization - Lean, variable-cost operations - Non-dilutive funding (e.g., grants, foundations, and government-backed programs such as BARDA in the U.S. or EU innovation funds) - Option-based partnerships with pharma - CRO support aligned to clinical + investor milestones At Confidence Pharmaceutical Research, we work with companies facing real-world financial pressure — helping them do more with less while keeping trials on track. 🔗 Read the full blog here: https://lnkd.in/eXpQnyye #Biotech #CRO #ClinicalResearch #DrugDevelopment #BiotechFunding #ConfidenceCRO #Startups #LeanBiotech #NonDilutiveFunding #MilestoneDriven #ClinicalTrials

Meet Sushmitha Bobba, one of Confidence’s Clinical Project Managers, whose career and creativity show that resilience has many forms. Sushmitha’s path started as a research assistant, took her through study management, home healthcare, and CRO roles on both sponsor and CRO sides—and today she leads complex global projects at Confidence. Her days are dynamic: coordinating teams, problem-solving, and keeping trials on track. This year, she achieved something outside of research: publishing her memoir, Unbroken: A Journey from Silence to Strength. “Resilience isn’t about being unshaken—it’s about continuing forward, even when you’ve been broken.” Read more about Sushmitha’s journey (and her book) on our blog: https://lnkd.in/e4_NXdJE #ClinicalTrials #Leadership #Resilience #Unbroken #ConfidencePharma

Many teams treat orphan drug designation (ODD) like a reward at the end of the road. We think it belongs in the design phase—right next to your first protocol draft. If you’re targeting a rare condition: - FDA defines it as <200,000 patients in the U.S. - EMA calls it <5 in 10,000 people in the EU. What’s often missed: - ODD isn’t just regulatory shorthand—it changes the economics of your trial. - It brings 7–10 years of exclusivity, tax credits, and early agency feedback that can actually shape your study design. - Many companies do apply as early as possible, but we still see cases where ODD is treated as a late check‑the‑box instead of a core part of protocol planning. At Confidence, we help teams map the path from first-in-human through pivotal studies— with ODD strategy baked in, not bolted on. Working on something rare? Let’s talk. #OrphanDrugDesignation #RareDisease #BiotechStrategy #ClinicalTrialDesign #DrugDevelopment #ClinicalTrial

We’re kicking off a new blog series: Rescue Studies. In Part 1, Rescue Rangers: How Confidence Takes Over and Rejuvenates Ailing Studies, we pull back the curtain on what really happens when a clinical trial starts to lose momentum—and how a focused takeover can bring it back to life. From rethinking feasibility to re-engaging sites and re-igniting patient enrollment, our team doesn’t just “fix issues,” we rebuild trust, re-align the plan, and set the trial on a new path forward. This is just the first chapter in a series where we’ll share what it really takes to rescue, restructure, and reaccelerate clinical trials. Read the full story here: https://lnkd.in/eU53UFWx